ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib (BMS-354825; Figure 6) was the first dual SRC-ABL inhibitor to enter the clinic and was developed starting from a series of substituted thiazole-5-carboxamides with activities against SRC and ABL and antiproliferative activity in CML cell lines and xenograft models [114]; besides SRC and ABL, dasatinib binds over 30 kinases, including major regulators of the immune system [115].